Have a personal or library account? Click to login
Ellipticine cytotoxicity to cancer cell lines - a comparative study Cover

Ellipticine cytotoxicity to cancer cell lines - a comparative study

Interdisciplinary Toxicology
Volume 4 (2011): Issue 2 (June 2011)
By: Marie Stiborová,  Jitka Poljaková,  Eva Martínková,  Lucie Bořek-Dohalská,  Tomáš Eckschlager,  Rene Kizek and  Eva Frei  
Open Access
|Jun 2011

References

  1. Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudeček J, Václavíková R., Frei E. (2007). The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos 35: 1926-1934.
    Search in Google Scholar
  2. Auclair C. (1987). Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259: 1-14.
    Search in Google Scholar
  3. Bořek-Dohalská L, Frei E and Stiborová M. (2004). DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615.
    Search in Google Scholar
  4. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B and Schwabe D. (1997). Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs 8: 958-63.
    Search in Google Scholar
  5. Frei E, Bieler CA, Arlt VM, Wiessler M and Stiborová M. (2002). Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-295.
    Search in Google Scholar
  6. Garbett NC and Graves DE. (2004). Extenting nature's leads: the anticancer agent ellipticine. Curr Med Chem Anti-Cancer Agents 4: 149-72.
    Search in Google Scholar
  7. Huska D, Adam V, Krizkova S, Hrabeta J, Eckschlager T, Stiborova M and Kizek R. (2010a) An electrochemical study of interaction of an anticancer alkaloid ellipticine with DNA. Chim Oggi-Chem Today 28(5) Suppl S: 15-17.
    Search in Google Scholar
  8. Huska D, Adam V, Hubalek J, Trnkova L, Eckschlager T, Stiborova M, Provaznik I and Kizek R. (2010b). Off-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction. Chim Oggi-Chem Today 28:(5) Suppl S: 18-20.
    Search in Google Scholar
  9. Fossé P, René B, Charra M, Paoletti C and Saucier JM. (1992). Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42: 590-595.
    Search in Google Scholar
  10. Froelich-Ammon SJ, Patchan MW, OsheroffN and Thompson RB. (1995). Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270: 4998-5004.
    Search in Google Scholar
  11. Kuo PL, Hsu YL, Chang CH and Lin CC. (2005a). The mechanism of ellipticineinduced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223: 293-301.10.1016/j.canlet.2004.09.04615896464
    Search in Google Scholar
  12. Kuo PL, Hsu YL, Kuo YC, Chang CH and Lin CC. (2005b). The antiproliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 16: 789-795.10.1097/01.cad.0000171768.36317.9316027529
    Search in Google Scholar
  13. Kuo PL, Kuo YC, Hsu YL, Cho CY and Lin CC. (2006). Ellipticine induced apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 78: 2550-2557.
    Search in Google Scholar
  14. Martinkova E, Dontenwill M, Frei E and Stiborova M. (2009). Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett 30 (Suppl 1): 60-66.
    Search in Google Scholar
  15. Martinkova E, Maglott A, Leger, DY, Bonnet D, Stiborova M, Takeda K, Martin S and Dontenwill M. (2010). α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 127: 1240-1248.
    Search in Google Scholar
  16. McCormick DL, Adamowski CB, Fiks A, Moon RC. (1981). Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea, Cancer Res 41: 1690-1694.
    Search in Google Scholar
  17. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J Jr and Fermandjian S. (1991). DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25: 1820-1829.
    Search in Google Scholar
  18. Moserová M, Kotrbová V, Rupertová M, Naiman K, Hudeček J, Hodek P, Frei E and Stiborová M. (2008). Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 29: 728-732.
    Search in Google Scholar
  19. Ohashi M, Sugikawa E and Nakanishi N. (1995). Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86: 819-829.
    Search in Google Scholar
  20. Poljaková J, Dračínský M, Frei E., Hudeček J and Stiborová M. (2006). The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect Czech Chem Commu. 71: 1169-1185.
    Search in Google Scholar
  21. Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hraběta J and Stiborová M. (2007). DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252: 270-279.
    Search in Google Scholar
  22. Poljaková J, Eckschlager T, Hraběta J, Hřebačková J, Smutný S, Frei E, Martínek V, Kizek R and Stiborová M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77: 1466-1479.
    Search in Google Scholar
  23. Singh MP, Hill GC, Peoch D, Rayner, B, Inabach, JL and Lown JW. (1994). Highfield NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33: 10271-10285.
    Search in Google Scholar
  24. Stiborová M, Bieler CA, Wiessler M and Frei E. (2001). The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 675-684.
    Search in Google Scholar
  25. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M and Frei E. (2003a). DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107: 885-890.10.1002/ijc.1151114601046
    Search in Google Scholar
  26. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003b). Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47.10.1021/tx020081812693029
    Search in Google Scholar
  27. Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M and Frei E. (2004). The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64: 8374-8380.
    Search in Google Scholar
  28. Stiborová M, Rupertová M. Schmeiser HH and Frei E. (2006). Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 13-23.
    Search in Google Scholar
  29. Stiborová M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T and Frei E. (2007a). Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120: 243-251.10.1002/ijc.2224717066455
    Search in Google Scholar
  30. Stiborová M, Rupertová M, Aimová D, Ryšlavá H and Frei E. (2007b). Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60.10.1016/j.tox.2007.03.02617482743
    Search in Google Scholar
  31. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudeček J, Phillips DH and Frei E. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-327.
    Search in Google Scholar
  32. Stiborová M, Rupertová M and Frei E. (2011). Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its antitumor efficiency. Biochim Biophys Acta 1814: 175-185.
    Search in Google Scholar
  33. Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N and Ohashi M. (1999). Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19: 3099-3108.
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10102-011-0017-7 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Journal RSS Feed
Language: English
Page range: 98 - 105
Published on: Jun 17, 2011
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Ellipticine,
cancer cell lines,
DNA adducts,
mechanims of acticancer effects of ellipticine
Related subjects:
Medicine,
Clinical medicine,
Pharmacology, toxicology

© 2011 Marie Stiborová, Jitka Poljaková, Eva Martínková, Lucie Bořek-Dohalská, Tomáš Eckschlager, Rene Kizek, Eva Frei, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.

Volume 4 (2011): Issue 2 (June 2011)